Promising Phase 3 info For Ustekinumab (Cnto 1275) In lengthy-Term Improvement Of Chronic Plaque Psoriasis

March 03rd, 2008 | Category: Dermatology

One-year details from the second double blind, placebo-controlled Phase 3 study PHOENIX 1 showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement

in the treatment of moderate to severe plaque psoriasis through one year.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
  • Long-Term Improvement Of Chronic Plaque Psoriasis Shown In Ustekinumab Phase 3 Data
  • Centocor And Janssen Cilag Submit Applications Requesting Approval Of Ustekinumab In The U.S. And Europe For Treatment Of Severe Plaque Psoriasis
  • Centocor Announces Ustekinumab Biologic License Application Accepted For Filing By FDA
  • Efalizumab Is Safe For faraway-Term Use In Psoriasis Patients

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.